Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient

Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient

Abstract Objective Immune-related adverse events (irAEs) are recognized in oncology, particularly with immune checkpoint inhibitors and other targeted therapies. Brentuximab Vedotin (BV), is an anti-CD30 antibody–drug conjugate- its association with immune-mediated myositis remains unexplored. We re...

Full description

Saved in:
Bibliographic Details
Main Authors: Adela Della Marina, Lydia Rink, Andreas Hentschel, Michael M. Schündeln, Christopher Nelke, Heike Kölbel, Calvin Tucht, Vera Dobelmann, Tobias Ruck, Tim Hagenacker, Teresinha Evangelista, Ulrike Schara-Schmidt, Andreas Roos
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Acta Neuropathologica Communications
Subjects:
Myositis
Anti-CD30
Brentuximab vedotin
Chemotherapy
Hodgkin lymphoma
Online Access:https://doi.org/10.1186/s40478-025-02056-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1186/s40478-025-02056-2

Similar Items